Effects of whole cottonseed diet and recombinant bovine somatotropin on ovarian follicles in lactating dairy cows

The effects of whole cottonseed (WCS) in the diet and the administration of bovine somatotropin (bST) on ovarian follicular dynamics and plasma progesterone (P4) concentrations were examined in cows during a period of synchronized follicular growth. Lactating Holstein cows (n = 28) were randomly assigned to treatments in a 2 x 2 factorial arrangement. Diets consisted of WCS (15% of dry matter) or no WCS, and bST at a dose of 0 or 208 mg/14 d. Dietary treatments began within 24 h of calving and bST treatments began within 7 d postpartum. Cows received GnRH at 65 +/- 3 d postpartum (d 0), PGF2alpha, (d 7), a second dose of GnRH (d 9), and were inseminated 16 h later (d 10). Ovarian changes were monitored daily by ultrasonography from d 0 to 9. On d 9,93% of cows had a preovulatory follicle and 86% ovulated. For Class 2 (6 to 9 mm) follicles, a diet x bST interaction was detected, with bST stimulating Class 2 follicles in cows fed WCS, but not in cows on the control diet. Neither diet nor bST affected numbers of Class 1 (2 to 5 mm) or Class 3 (> or = 10 mm) follicles or sizes of the subordinate and dominant follicles. During the luteal phase of the cycle, lactating cows fed WCS tended to have elevated concentrations of plasma P4, whereas bST was without effect. Plasma concentrations of high-density lipoprotein cholesterol were increased in cows fed WCS. Number and diameter of corpora lutea did not differ among treatments.     

Effect of recombinant bovine somatotropin on milk production and composition of cows with Streptococcus uberis mastitis.

The protective effect of bovine somatotropin (bST) during experimental Streptococcus uberis mastitis in cows was studied. The left quarters of 10 cows were infected with 500 cfu of S. uberis O140J. Five cows were subcutaneously treated with 500 mg of recombinant bST 7 d before and after infection, and 5 control cows received the excipient. In the treated cows, total milk production significantly increased after the first and second bST treatments. After infection, milk production decreased 24 and 40% in the infected quarters, 6 and 14% in the uninfected quarters, and 15 and 28% overall for treated and control cows, respectively. In the bST group, milk production was completely restored after 3 wk, but, in the control group, total production and the production of the infected quarters remained lower than preinfection production. The increase in somatic cell count occurred earlier and more rapidly in the control group, and the return to normal values was also more rapid in these cows. The amount of bacteria in milk was higher in the control cows. Changes in milk composition, such as lactose, protein, fat, Na+, K+, and Cl-, were significantly more pronounced in the control cows. Also, clinical symptoms were more prominent in the control cows. Somatotropin protected the mammary gland from excessive production losses and compositional changes during a subsequent episode of experimentally induced Streptococcus uberis mastitis and significantly improved the normalization of production and composition, which indicates a beneficial effect on the restoration of the integrity of the blood-milk barrier.     

Responses of high-producing dairy cows to long-term treatment with pituitary somatotropin and recombinant somatotropin

Thirty Holstein cows capable of high milk production were utilized to examine the effects of long-term administration of bovine somatotropin on lactational performance. Treatments were 0 (control), 13.5, 27, and 40.5 mg/day of recombinantly-derived bovine somatotropin and 27 mg/day of pituitary-derived bovine somatotropin. Hormone was injected intramuscularly, once daily beginning at 84 +/- 10 days postpartum and continuing for 188 days. Cows were fed ad libitum a total mixed diet throughout the lactation. Recombinant somatotropin treatments increased average fat-corrected milk yield in a dose-dependent fashion from 23 to 41% over the control production (27.9 kg/day. Pituitary somatotropin (27 mg/day) increased milk production by 16%. Milk lactose, protein, and fat composition was similar for all treatments. Control cows were in positive energy balance throughout the treatment period (4.7 Mcal net energy/day. Initially, the large increase in milk yield with somatotropin treatment caused cows to decrease in energy balance. However, voluntary intake gradually increased, and by week 10 of treatment all somatotropin treatment groups were in positive energy balance. Thus, the gain in body weight over the treatment period was similar for all groups, ranging from 17 to 22%. Gross lactational efficiency (milk per unit of net energy intake) was improved by exogenous somatotropin whether calculated as observed, corrected for body weight changes, or using the theoretical energy requirements for maintenance and milk production. Results are consistent with bovine somatotropin as a homeorhetic control that coordinates an array of physiological processes so that nutrients are partitioned for milk synthesis.     

Effects of recombinant bovine somatotropin on nutritional status and liver function of lactating dairy cows

Twenty-four high producing, multiparous Holstein cows were utilized to evaluate effects of long-term administration of sustained-release rbST on blood pH, gases, buffer capacity, circulating metabolites and hormones, and on liver lipid content and functions during lactation. Treatment, commencing 98 to 112 d postpartum and continued until d 305, consisted of a subcutaneous injection of a placebo or 350 mg of rbST every 14 d. Milk and 3.5% FCM were increased significantly by rbST, but milk fat and protein content, feed intake, energy balance, corrected feed efficiency for milk production, and body condition scores were unaffected. Somatotropin decreased blood pH and buffer capacity by decreasing bicarbonate without affecting blood partial pressures of oxygen or carbon dioxide. Concentration of plasma albumin was decreased and nonesterified fatty acids, glucose, insulin, rbST and insulin-like growth factor-I were increased by treatment. Total plasma proteins and cortisol, hemoglobin, and hematocrit were unaffected. Liver DM, total lipid and triacylglycerol contents, and plasma 3-hydroxybutyrate and glutamic oxalacetic transaminase were not affected by rbST, but the percentage of triacylglycerol in total lipids was increased. Results of this experiment suggest that rbST exhibited lipolytic and diabetogenic activities in lactating dairy cows in vivo and that these effects might be important for the increase in nutrient partitioning toward the mammary gland elicited by rbST.     

Growth hormone-releasing factor stimulates milk production and sustains growth hormone release in Holstein cows

Serum growth hormone was determined in lactating cows following repeated intravenous injections of growth hormone-releasing factor. A given dose was injected every 4 h for 24 h in a 4 (cow) X 4 (d) Latin square. Growth hormone increased similarly above controls after 10, 20, or 40 micrograms releasing factor/100 kg body weight. In another experiment the effects on lactational performance and growth hormone responses of cows to repeated injections of releasing factor for 10 d were determined in a 2 (cow) X 2 (period) Latin square crossover. Administration of 20 micrograms releasing factor/100 kg body weight to 16 Holstein cows (lactating 4.5 to 7.5 mo) every 4-h for 10 d increased milk yield from 25.4 to 27.7 kg/d and increased total fat, protein, and lactose 11% above controls. Releasing factor did not affect milk composition or feed intake. Peak growth hormone response to releasing factor was similar between d 1 (19.9 ng/ml) and 10 (24.4 ng/ml). Exogenous growth hormone-releasing factor administered to lactating Holstein cows at the doses tested: 1) increases growth hormone consistently, although the response is not dose dependent, 2) is galactopoietic, 3) causes an apparent increase in feed to milk conversion, and 4) increases growth hormone to at least the same magnitude on d 10 as on d 1.     

Effects of diet and injection of bovine somatotropin on prepubertal growth and first-lactation milk yields of Holstein cows

To determine effects of rapid prepubertal growth on first-lactation milk production, Holstein heifers were randomly assigned to one of three treatments. Thirty-five heifers were fed a standard diet to meet NRC recommendations and produce 0.8 kg of body weight (BW) gain/d (standard). Thirty-five heifers were fed a diet with higher energy (2.8 Mcal of metabolizable energy/kg) and protein (19.7% crude protein; high diet) to produce 1.2 kg of BW gain/d (high). Thirty-five heifers were fed the high diet and injected daily with bovine somatotropin (bST) (25 microg/kg of BW; high-bST). Diets were fed and bST was injected from 135 kg of BW until pregnancy was confirmed. Heifers were inseminated after BW exceeded 363 kg. Pregnant heifers were commingled and fed similar diets through gestation, parturition, and lactation. High and high-bST heifers had greater prebreeding average BW gains than standard heifers. Conversely, standard heifers had a greater average BW gain during gestation than high and high-bST heifers. High and high-bST heifers were approximately 90 d younger than standard heifers at first insemination and first parturition. Postpartum BW, body condition scores, and withers heights at parturition, and calving ease scores were not different among treatments. Standard heifers produced 14% more milk than high heifers but not more than high-bST heifers. The high-protein, high-energy diet decreased age at first parturition and first-lactation milk production, but did not affect reproduction. Injection of bST during the prepubertal growth period combined with the high diet decreased age at first parturition without reducing milk production.     

Contact sensitivity and systemic antibody responses in dairy cows treated with recombinant bovine somatotropin.

Effects of exogenous bST on humoral and cell-mediated immune responses in lactating dairy cows were determined. The systemic antibody response to human erythrocytes and the cutaneous sensitivity response induced by dinitrochlorobenzene were the immune responses investigated. Cows were treated with either 0, 10.3, or 20.6 mg of bST/d for 266 d starting between wk 4 and 5 of lactation. Systemic immunizations and contact sensitivity were initiated during midlactation, 22 wk after bST treatments began. Hemagglutinating antibody titers and areas under the response profiles were not statistically different for bST-treated versus control cows. The cutaneous sensitivity response was similarly not affected by bST administration. Present antibody titer results agreed with our previous observations that bST did not affect serum IgM concentrations, but the cutaneous sensitivity results were in contrast with our finding of augmented proliferative responsiveness of mitogen-stimulated peripheral blood lymphocytes in bST-treated versus control cows. It is possible that exogenous bST affects some immune processes and lymphocyte subsets and not others. Further research is required to determine the practical significance of the variable immunomodulation elicited by exogenous bST.     

Lactation performance of Holstein cows treated with 2 formulations of recombinant bovine somatotropin in a large commercial dairy herd in Brazil

The objectives of this controlled study were to compare the effects of 2 different formulations of recombinant bovine somatotropin (rbST) on milk yield, milk composition (fat and protein), milk somatic cell count, and body condition score (BCS) among dairy cattle in a large commercial herd. Regulatory approved 500-mg zinc sesame oil base rbST (ZSO-rbST; Elanco Animal Health, Greenfield, IN) and vitamin E lecithin base rbST (VEL-rbST; LG Life Sciences, Seoul, South Korea) formulations were administered per the manufacturers' recommendations every 14 d over 17 injection cycles starting at 57 to 70 d of lactation (90 cows per rbST group). Control cows (n = 60) received no rbST. Somatotropin-treated animals (VEL-rbST and ZSO-rbST combined) had increased average milk yield and protein percentage and lower average BCS compared with control cows. For primiparous cows, average milk yield was 37.75 kg/d with the ZSO-rbST treatment and 35.72 kg/d with the VEL-rbST treatment. For multiparous cows, average milk yield was 40.13 kg/d with the ZSO-rbST treatment and 38.81 kg/d with the VEL-rbST treatment. There were no differences in milk fat percentage between VEL-rbST and ZSO-rbST treatments, but milk protein content was greater with VEL-rbST treatment than with ZSO-rbST treatment. Nonetheless, cows treated with ZSO-rbST yielded more kilograms of fat and protein per day than cows treated with VEL-rbST. No significant differences in BCS were found between both rbST treatment groups. The differential increase in milk yield between cows treated with ZSO-rbST and VEL-rbST was driven by rbST response differences both within the 14-d cycle and throughout the 17 injection cycles. The cows treated with VEL-rbST demonstrated a more variable 14-d milk yield response curve, with more pronounced valleys between injections compared with the ZSO-rbST formulation. In addition, only the ZSO-rbST treatment was effective in modifying the lactation persistency compared with control cows. Compared with the VEL-rbST formulation, the ZSO-rbST formulation yielded more kilograms of milk, fat, and protein with less milk variation throughout the seventeen 14-d lactation cycles for both primiparous and multiparous cows.     

Serum immunoglobulin profiles of dairy cows chronically treated with recombinant bovine somatotropin

The objective of this study was to determine the effects of exogenous somatotropin on blood profiles of the major bovine Ig isotypes. Holsteins were treated with either 0, 10.3, or 20.6 mg recombinant bST/d. Subcutaneous injections were started between wk 4 and 5 of lactation and continued for 266 d. Blood samples were collected by coccygeal venipuncture throughout lactation for serum IgG, G1, G2, A, and M concentration determination. Cows treated with 10.3 mg of bST/d exhibited modest increases in mean blood concentrations of IgG (12.4%) and IgG2 (18.4%) relative to the other groups of cows. In addition, treated cows had 10.1% higher average concentration of IgA than controls. Somatotropin did not influence average lactational concentrations of IgG1 or IgM, although the group receiving 10.3 mg/d had higher late lactation concentrations of IgG1 than did the other two groups. However, treatment mean isotype concentrations were always within normal ranges, except for IgG2 from the 10.3 mg/d group, which were higher. The practical significance of elevated serum Ig concentrations observed in the present study is not known. However, the present data do show that bST administered at doses that increased milk yield had no apparent detrimental effect on humoral immunity as measured by blood concentrations of Ig.     

Effect of prepartum administration of recombinant bovine somatotropin on health and performance of lactating dairy cows

A double-blind, randomized clinical trial was conducted in 5 commercial dairy herds in southern Ontario with 1,362 cows enrolled to evaluate the effect of prepartum administration of recombinant bovine somatotropin (rbST) on health and performance. Cows were randomly assigned to receive either 325 mg of sometribove zinc suspension (n = 680) or a placebo injection (n = 682; control) subcutaneously every 14 d until calving. Treatments started 28 to 22 d before expected calving, with a maximum of 3 treatments per cow. Serum samples taken at the time of enrollment, 1 wk before calving, and weekly for 3 wk after calving were analyzed for nonesterified fatty acids (NEFA), β-hydroxybutyrate (BHBA), glucose, aspartate aminotransferase, calcium, and haptoglobin. Diseases were recorded by farm staff. Incidences of clinical ketosis, clinical mastitis, displaced abomasum, metritis, retained placenta, milk fever, and lameness were similar between groups. Body condition score was lower for treated than for control cows at 3 wk after calving (3.13 and 3.17, respectively). Serum NEFA tended to be higher for treated than for control cows by 0.01 mmol/L. Overall BHBA was not different between groups, but BHBA for treated cows was higher in wk 1 after calving (750 and 698 μmol/L, respectively) and tended to be higher in wk 2 after calving (779 and 735 μmol/L, respectively). Incidence of hyperketonemia was similar between groups. Treated cows had higher serum glucose compared with control cows (2.8 and 2.7 mmol/L, respectively). We detected no differences in serum aspartate aminotransferase, calcium, or haptoglobin between groups. Milk yield was recorded daily for each cow for 63 d, and did not differ between groups (37.1 ± 0.5 kg and 36.7 ± 0.5 kg, respectively) but we detected a tendency for treated cows to produce 0.8 kg/d more milk than control cows in wk 1 after calving. We observed no difference between groups in the time from calving to first insemination or the probability of pregnancy at the first insemination. Groups did not differ in the proportion of anovular cows at 53 ± 3 d in milk based on serum progesterone measured from a subset of cows (38.0 and 34.3%, respectively, for treated and control groups). We found no difference between groups in dry matter intake from 21 d before calving to 63 d after calving in a subset of cows (17.4 ± 0.4 and 17.5 ± 0.4 kg/d, respectively). Based on results of the current study, biweekly (every 14 d) administration of rbST before calving to prevent disease and enhance performance is not recommended.     

Treatment of dairy cows with recombinant bovine somatotropin: genetic and phenotypic aspects

Thirty-four multiparous and primiparous Holstein cows were utilized to examine the association between the response to long-term administration of recombinant bovine somatotropin and the cow's phenotypic and genetic production potential. Cows representing a range of phenotypic and genetic production potentials were assigned to one of four treatment groups: 0, 12.5, 25.0, or 50.0 mg recombinant bovine somatotropin daily. They were injected daily for 266 d beginning on d 24 to 35 postpartum. Pretreatment milk and fat yields were used to predict daily yields over the lactation and allowed treatment groups to serve as their own controls. Actual minus predicted yield estimated the response to treatment for milk, fat, and FCM for each cow. Milk composition (fat, protein, and lactose percentage) was not significantly affected by treatment. Response in yield for milk, fat, and FCM was significant during the treatment period (266 d). Milk yield increased by 18.5, 19.9, and 21.4%; fat yield increased by 13.4, 20.3, and 18.1%; and FCM increased by 16.3%, 19.7%, and 21.1% after receipt of 12.5, 25.0 and 50.0 mg recombinant bovine somatotropin, respectively. Differences in response were not significant. The dramatic effect recombinant bovine somatotropin has on production requires that alternative approaches be adopted in the future for accurate genetic evaluation of sires and dams if somatotropin is discriminantly used in the national herd.     

Supplementing Holstein cows with low doses of bovine somatotropin prepartum and postpartum reduces calving-related diseases

The objective of this study was to evaluate whether supplementing Holstein cows with bovine somatotropin (bST; 142.8 mg/14 d), beginning at 21 d (±3 d) before expected calving and continuing through 42 d in milk (±3 d), affected the incidence rates of retained fetal membranes (RFM), metritis (MET), clinical mastitis (MAS), digestive problems (DIG), ketosis (KET), milk fever (MF), displaced abomasum (DA, left or right), lameness (LAM), or number of sick cows during the first 60 d in milk. Data for multiparous Holstein cows from 3 separate trials were merged for analyses (n = 437). Cows in the bST-supplemented group (n = 162) received biweekly subcutaneous injections of Posilac, whereas control cows (n = 166) and a group of cohorts (n = 109) were not supplemented. Incidences of disease were collected from the herd health records. Across all treatment groups, the incidence rates (number of diseased cows divided by the total number of cows) for RFM, MET, MAS, DIG, KET, MF, DA, and LAM were 8.47, 18.31, 16.02, 4.35, 4.35, 3.66, 3.20, and 3.66%, respectively. The incidence rates of RFM, MET, MAS, DIG, KET, MF, DA, and LAM for cows in the bST-supplemented, control, and cohort groups were 6.79, 7.83, and 11.93%; 16.05, 7.47, and 22.94%; 10.49, 18.07, and 21.10%; 1.23, 5.42, and 7.34%; 1.23, 6.02, and 6.42%; 2.47, 4.22, and 4.59%; 2.47, 3.61, and 3.67%; and 3.70, 3.61, and 3.67%, respectively. The percentages of sick cows (number of cows having one or more cases of disease divided by the total number of cows) in the bST-supplemented, control, and cohort groups were 33.95, 43.37, and 49.54%, respectively. Significant chi-squared values were detected between the bST-supplemented and control groups for MAS, DIG, and KET, with a greater number of healthy cows in the bST-supplemented group. No differences in incidences of diseases or sick cows were detected between the control and cohort groups. Results indicated that a low dose of bST supplemented to Holstein cows for 3 wk prepartum through 60 d in milk reduced the incidences of some calving-related diseases compared with nonsupplemented controls or cohorts. Importantly, no negative effects of bST supplementation on postpartum calving diseases were detected compared with nonsupplemented cows.     

Somatotropin antibody formation in cows treated with a recombinant bovine somatotropin over two lactations

Blood plasma from cows treated with somidobove, a form of recombinant bovine somatotropin, was assayed for development of antibodies against the protein. Forty-three Holstein cows, selected from an animal safety study, were monitored. Cows were divided into four groups and treated with placebo, 960, 2880, or 4800 mg somidobove per dose at 28-d intervals during two successive lactation periods. Blood plasma was collected at intervals prior to and during the lactations, and levels of IgG antibody reactive with somidobove were determined in an enzyme-linked immunosorbent assay. Virtually all of the cows treated with somidobove developed low levels (less than 40 micrograms/ml) of antibody against somidobove. One or two cows from each group responded with some-what higher levels, ranging from 40 to 200 micrograms/ml. Responses generally increased during the first 3 mo of treatment, then decreased, and remained constant with continued treatment. There was no sign of a memory response within or among the lactation periods, and no adverse health effects or decreases in lactational performance were associated with antibody production.     

Effect of recombinant bovine somatotropin on estradiol-induced estrous behavior in ovariectomized heifers.

To evaluate whether bST administration could affect the intensity of estrous behavior in the absence of the ovary, 17 ovariectomized heifers were assigned to receive a placebo or 500 mg/14 d of recombinant bST and were induced to display behavioral estrus by administration of 2 mg of estradiol cypionate. Estrous behavior was monitored for the following 60 h with a surveillance camera and a video recorder, and mounting activity was quantified. Blood samples were collected before and after bST administration. Administration of bST numerically elevated plasma insulin and NEFA and caused a significant increase in concentration of insulin-like growth factor-I in plasma. Heifers that received bST started to display estrous behavior later (24.5 +/- 1.1 and 21.9 +/- 1.1 h after estradiol administration for bST and placebo treatments, respectively), displayed estrous behavior of shorter duration (bST, 13.2 +/- 1.2 vs. placebo, 15.8 +/- 1.1 h), and instigated fewer mounting events (bST, 45.5 +/- 5.9 vs. placebo, 62.6 +/- 5.7 mounts) than control heifers, although only the number of mounting events was significantly different between the two groups.     

Response to recombinant bovine somatotropin in dairy cows with different genetic merit for milk production

Thirty-nine multiparous cows obtained from two genetic lines were utilized to determine the effect of genetic merit on lactation response to long-term administration of recombinant bST. Cow index ranged from -70 to 456 (mean = 183) and -494 to -88 (mean = -288) kg milk for high and low genetic groups, respectively. Cows were blocked by calving date and randomly assigned to treatment within genetic group. Treatments were 0, 10.3, 20.6, and 30.9 mg somatotropin injected daily from wk 14 through 44 postpartum. Cows were fed one of two total mixed rations. Diet 1 (NE1 = 1.65 Mcal/kg, CP = 18%, and ADF = 22%) was fed from start of lactation to at least 4 wk after initiation of treatment. Cows were switched to diet 2 (NE1 = 1.56 Mcal/kg, CP = 16%, and ADF = 27%) when milk output fell below 25 kg/d. Forty-four week lactation yields were 9800 and 9447 kg milk; 364 and 354 kg fat; and 322 and 309 kg protein for high and low genetic groups, respectively. Milk, milk fat, or protein yield due to somatotropin did not differ between genetic groups. Increasing dosage of bST increased milk, 4% FCM, fat, and protein yields in a linear fashion. Percentages of fat and protein of milk were similar for all treatment groups. Body weight changes were not significantly different among treatments, but condition score changes decreased linearly with increasing dose of bST. Long-term treatment with recombinant bST had no apparent effect on incidence of health problems or reproduction.     

Effect of season, genetic line, and sire on growth concentrations of somatotropin in serum of Holstein cows in early lactation.

To determine the effect of selection for milk yield on somatotropin concentrations, blood samples were collected from 128 Holstein cows whose sires had either high or average predicted differences for milk. The phenotypic difference in milk yield between the high and average yielding groups was 1726 kg on a 305-d mature equivalent basis. At 37 +/- 7 d postpartum, four blood samples were taken from each cow at 1-h intervals beginning at 0800 h. The statistical model contained genetic line, sires within line, and season as whole-plot effects and time of sampling as a subplot effect. The concentration of growth hormone was significantly higher in the high yielding group (1.89) than in the average yielding group (1.49). Cows sampled in summer had the highest concentrations of growth hormone, whereas cows sampled in spring had the lowest concentrations. Sires did not significantly influence the somatotropin concentration of their progeny. In a second analysis with seven extreme outliers (peak values) deleted, the variation of somatotropin concentrations in the cows was significantly accounted for by their sires. Repeatability of somatotropin concentration was .49 within cows.     

Effects of treatment of periparturient dairy cows with recombinant bovine somatotropin on health and productive and reproductive parameters

The objectives of the current experiment were to evaluate the effects of treating periparturient dairy cows with recombinant bovine somatotropin (rbST) on incidence of postpartum diseases and performance. Holstein (HO) and Jersey (JS) cows from 2 herds were enrolled in the experiment at 253 ± 3 d of gestation and assigned to the control (n = 432) and rbST125 (n = 437) treatments. Cows in the rbST125 treatment received 125 mg of rbST, weekly, from ?21 to 21 d relative to calving. Blood sampled weekly, from ?21 to 21 d relative to calving, from a subsample of cows was used to determine the concentrations of growth hormone (GH, HO = 106) and insulin-like growth factor 1 (IGF-1, HO = 147 and JS = 49). Cows were scored for body condition (BCS) at enrollment and at 1 ± 3, 30 ± 3, and 60 ± 3 d in milk (DIM). Cows were milked thrice daily and energy-corrected milk (ECM) yield was recorded for the first 30 DIM. Treatment of cows with rbST resulted in greater concentrations of GH during the prepartum (log₁₀ back-transformed concentrations of GH: HO-control = 7.83 and HO-rbST125 = 10.36 ng/mL) and postpartum (log₁₀ back-transformed concentrations of GH: HO-control = 10.45 and HO-rbST125 = 18.47 ng/mL) periods. Similarly, IGF-1 concentrations were higher during the prepartum (HO-control = 115.1 ± 4.9, HO-rbST125 = 137.7 ± 4.7, JS-control = 120.2 ± 8.3, JS-rbST125 = 167.1 ± 8.1 ng/mL) and postpartum (HO-control = 61.3 ± 4.0, HO-rbST125 = 75.2 ± 3.8, JS-control = 35.5 ± 6.9, JS-rbST125 = 54.6 ± 6.9 ng/mL) periods for rbST-treated cows. During the prepartum period, BCS was not affected by treatment, but during the postpartum period, BCS was reduced for rbST-treated cows (HO-control = 3.00 ± 0.03, HO-rbST125 = 2.90 ± 0.03, JS-control = 2.64 ± 0.02, JS-rbST125 = 2.61 ± 0.02). Cows from the rbST125 treatment tended to have lower incidence of retained fetal membranes (HO-control = 14.3, HO-rbST125 = 6.1, JS-control = 1.5, JS-rbST125 = 1.2%) and had reduced incidence of metritis (HO-control = 26.2, HO-rbST125 = 16.6, JS-control = 19.9, JS-rbST125 = 13.3%) compared with control cows. Ketosis incidence tended to be higher for rbST125 cows (HO-control = 9.4, HO-rbST125 = 11.3, JS-control = 8.5, JS-rbST125 = 13.4%) compared with control cows. The interaction between treatment and herd tended to affect yield of ECM during the first 30 DIM because HO cows treated with rbST during the periparturient period had greater yield than control HO cows (HO-control = 35.5 ± 1.0 vs. HO-rbST125 = 39.4 ± 1.0 kg/d), but treatment with rbST did not affect yield of ECM of JS cows (JS-control = 26.7 ± 0.6 vs. JS-rbST125 = 27.8 ± 0.6 kg/d). Treatment of periparturient dairy cows with 125 mg of rbST decreased the incidence of uterine disorders in HO and JS cows and increased yield of ECM during the first 30 DIM among HO cows, despite slightly increasing the incidence of ketosis.     

Effect of recombinant bovine somatotropin and a shortened or no dry period on the performance of lactating dairy cows

The objective of this study was to determine the effects of altering dry period length in multiparous dairy cows (n = 341) on milk production for a full lactation (294 d). The study used 3 commercial herds in the western United States. Cows producing greater than 8,400 kg of mature-equivalent milk were assigned to treatments 60 d before their due dates. The 4 treatments were 1) 60-d dry period, label use of recombinant bovine somatotropin (rbST; 60d-L); 2) 32-d dry period, label use of rbST (32d-L); 3) 0-d dry period, label use of rbST (0d-L); and 4) 0-d dry period, continuous use of rbST (0d-C). Cows with shortened dry periods produced 625, 1,000, and 1,042 kg of milk during the prepartum period for treatments 2 to 4, respectively. During the postpartum period, cows on the 32d-L treatment produced similar amounts of milk compared with the 60d-L treatment (11,490 vs. 11,968 kg, respectively). However, cows on the 0d-L (10,316 kg) and 0d-C (10,195 kg) treatments produced significantly lower amounts of milk during the postpartum period compared with the 60d-L treatment. Total milk production from the prepartum and postpartum periods was not altered significantly and was 11,974, 12,112, 11,310, and 11,230 kg for treatments 1 to 4, respectively. The concentrations of β-hydroxybutyrate and nonesterified fatty acids in serum after calving were decreased for cows on the 32d-L, 0d-L, and 0d-C treatments compared with cows on the 60d-L treatment, which may indicate improved metabolic status.     

Effects of bovine somatotropin on physiologic responses of lactating Holstein and Jersey cows during hot, humid weather

Thirty-one lactating Holstein and Jersey cows were used to determine the effects of daily injections of 0 or 20 mg of recombinant bST on physiologic responses during hot, humid weather. Body temperature was determined by measuring milk temperature at each milking. Jugular blood was sampled for serum analysis of selected hormones, blood metabolites, and fatty acids, and arterial blood was sampled for blood pH and blood gas analysis. Milk was characterized for fatty acid composition. Blood pH was unchanged, but partial pressure of blood CO2, blood bicarbonate, base excess, and total CO2 declined with administration of bST. Serum triglycerides increased 89% in cows receiving bST. Blood urea nitrogen tended to decline in cows receiving bST. Serum cortisol, triiodothyronine, and thyroxine did not change, but insulin-like growth factor-1 increased 128% with bST use. Reduced milk short-chain fatty acids, increased milk long-chain fatty acids, and increased blood serum C18:1 fatty acid content occurred in cows administered bST and probably reflected tissue mobilization. Cows administered bST in hot weather had higher milk temperatures. Alterations in physiologic and metabolic measures in association with higher milk temperature suggest an interaction of bST use with hot, humid weather and reflect the need to minimize the effects of heat stress.